Edison commences EPI-743 Phase IIb Friedreich's ataxia trial

Edison Pharmaceuticals has commenced a Phase IIb clinical trial of EPI-743, an orally bioavailable small molecule being developed for the treatment of Friedreich's ataxia and other inherited mitochondrial diseases.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news